Psychopharmacology Publishes Combined Analysis of Phase 2 Clinical Trials of MDMA-Assisted Therapy for PTSD
Thirteen Sites Screening Participants in Phase 3 Trials of MDMA-Assisted Therapy for PTSD
May 30, 2019
Dear friends and supporters,
Onward momentum at MAPS is ever-growing, and we’re pleased to share with you the advancements made in the field of psychedelic research this month. We’re proud to announce that the results of six MAPS-sponsored Phase 2 clinical trials of MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD) are published in the peer-reviewed journal Psychopharmacology. The double-blind, placebo-controlled trials in 103 subjects total found that 54% of participants in the active treatment group (75-125 mg MDMA) did not qualify for a diagnosis of PTSD after two MDMA-assisted psychotherapy sessions and associated non-drug preparation and integration sessions, compared to 23% in the control group (0-40 mg MDMA). This paper is the most comprehensive analysis yet published of research into the efficacy and safety of MDMA-assisted psychotherapy for PTSD. • Read the Press Release
Thirteen of fifteen sites are officially screening for our U.S. Food and Drug Administration (FDA)-regulated Phase 3 clinical trial of MDMA-assisted psychotherapy for PTSD. Newly screening study sites are Madison, Wisconsin, Vancouver, British Columbia, Montreal, Canada, and Be’er Ya’akov, Israel. We anticipate the continued progress of our research will lead to FDA approval of the prescription use of MDMA-assisted psychotherapy as a prescription treatment for PTSD by the end of 2021.
The MAPS Bulletin Spring 2019 Special Edition: Women and Psychedelics is now available online and in subscriber mailboxes! In this publication, we celebrate and share perspectives of inspiring women who are researchers, therapists, healers, community leaders, and drug policy activists. Donate $50 or more and receive a one-year subscription to the printed Bulletin. • Browse the Bulletin
From May 8-13, 2019, 108 Zendo Project staff and volunteers provided psychedelic peer support for 164 attendees at the Lightning in a Bottle festival at the Buena Vista Aquatic Recreational Area in Bakersfield, Calif. The Zendo Project created comfortable spaces in two separate locations across the festival, allowing a more comprehensive approach for harm reduction services.
From May 30 through June 27, you are invited to join the Zendo Project and harm reduction experts for Beyond Therapy: Psychedelics in Everyday Life. This 5-part weekly webinar series explores the topic of navigating psychedelic experiences beyond a therapy setting. Tickets are available for individual sessions or the full series.
In this month’s edition of the MAPS Newsletter, you’ll also learn:
- Read our new statement: Public Announcement of Ethical Violation by Former MAPS-Sponsored Investigators
- MAPS and MAPS PBC have new career opportunities
- The MAPS Bulletin Spring 2019 Special Edition: Women and Psychedelics is now available online and in subscriber mailboxes
- The Science of Microdosing Psychedelics, the new book by Torsten Passie, M.D., is now available in the MAPS Store
- The MAPS Podcast features an interview with writer and consciousness researcher David Jay Brown
The generosity of our supporters continues to humble us. The Psychedelic Science Funders Collaborative (PSFC) has generously provided a $4,140,000 grant to support the expansion of our work. PSFC is a non-profit network of philanthropists dedicated to supporting research and clinical trials with psychedelic medicines and patient access to these treatments. PSFC was born in 2017 out of a realization that psychedelic medicine has the potential to make an enormous impact and has an achievable path to regulatory approval, but has been systemically underfunded. With this grant to MAPS, PSFC is making its first big contribution. • Read More
Through donations large and small, our work is made possible by all MAPS supporters. Thank you!
Follow MAPS on Facebook, Twitter, Instagram, YouTube, LinkedIn, and reddit.
Onward and upward!
With appreciation,
Amy Mastrine
MAPS Web and Email Marketing Associate
Treating PTSD with MDMA-Assisted Therapy
Phase 3 Trials of MDMA-Assisted Therapy for PTSD: 13 Sites Screening Participants
As of May 15, 2019, thirteen of fifteen sites are officially screening for our FDA-regulated Phase 3 clinical trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). Newly screening study sites are Madison, Wisconsin, Vancouver, British Columbia, Montreal, Canada, and Be’er Ya’akov, Israel.
Taking place at 15 locations across the United States, Canada, and Israel, study participants will be administered MDMA or placebo in conjunction with psychotherapy at research sites in the following locations:
- Charleston, SC
- Boulder, CO
- Fort Collins, CO
- Los Angeles, CA
- New Orleans, LA
- San Francisco, CA (UCSF and private practice)
- New York, NY (NYU and private practice)
- Boston, MA
- University of Wisconsin-Madison
- Vancouver, British Columbia
- Montreal, Canada
- Be’er Ya’akov, Israel
- Tel HaShomer, Israel (Sheba Medical Center)
Phase 3 clinical trials are assessing the efficacy and safety of MDMA-assisted psychotherapy in adult participants with severe PTSD. Over a 12-week treatment period, participants will be randomized to receive twelve non-drug preparatory and integration sessions lasting 90 minutes each along with three day-long sessions about a month apart of either MDMA or placebo in conjunction with psychotherapy. The primary endpoint will be the Clinician Administered PTSD Scale (CAPS-5), as assessed by a blinded pool of independent raters.
The trials are the final phase of research required by the FDA before deciding whether to approve MDMA-assisted psychotherapy as a legal prescription treatment for PTSD. If approved, MDMA will be required to be used in conjunction with psychotherapy in a clinical setting.
To learn more about currently recruiting national and international studies, visit our participate in research webpage. • Learn More
Therapist Training Study: 76th Participant Enrolls
On May 15, 2019, the 76th participant enrolled in our ongoing Phase 1 study of the psychological effects of MDMA when used in a therapeutic setting by healthy volunteers. Enrollment in this multi-site study is limited by invitation only to therapists in training to work on MAPS-sponsored clinical trials of MDMA-assisted psychotherapy for PTSD. The Boulder, Colorado, study site is led by Principal Investigator Marcela Ot’alora, M.A., L.P.C. Zhenya Gelfand, M.D., is serving as Principal Investigator at the site in Charleston, South Carolina, with Sub-Investigator Annie Mithoefer, B.S.N. • Learn More
Startle Testing with MDMA: Thirteenth Participant Receives Experimental Treatment
On May 1, 2019, the thirteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, Ph.D., this study is conducted at Emory University in Atlanta, Georgia. This research group is planning to conduct a subsequent study exploring the combination of MDMA with Prolonged Exposure in people with PTSD. • Learn More
Expanded Access Training Update: May 2019
The MDMA Therapy Training Program has launched a series of trainings to prepare therapy providers to become eligible to work on a MAPS-sponsored MDMA/PTSD protocol. On May 4-11, 2019, 53 therapists, doctors, and counselors gathered at Shambhala Mountain Center in Red Feather Lakes, Colorado, to receive training from Marcela Ot’alora M.A., L.P.C., and Bruce Poulter, R.N., on MDMA-assisted psychotherapy for PTSD in a six-and-a-half-day training retreat. Trainees represented more than 20 potential MDMA/PTSD research sites across 13 states. International guests hailed from Israel and Canada.
Applications remain open for the MDMA Therapy Training for Communities of Color event, taking place August 10-17, 2019 in Louisville, Kentucky, led by Marcela Ot’alora, M.A., L.P.C., and Monnica Williams, Ph.D., A.B.P.P., with support from additional trainers. More details about this event, including exact location, schedule, scholarship and registration fees, and line-up of guest presenters for the Psychedelic Medicine and Cultural Trauma Community Workshop August 10-11, will be available as they are updated on our event page. Scholarships will be available for therapy providers and community organizers of color through the generous contributions of Open Society Foundation, RiverStyx Foundation, and several other pledges that are in the works. Details on scholarship will be posted online as soon as they are available.
We are pleased to announce that an additional training retreat has been scheduled for September 29 – October 6, 2019 in Asheville, North Carolina. The training will be led by Annie Mithoefer, B.S.N., and Michael Mithoefer, M.D. Eligible therapy providers interested in this event can submit the MDMA Therapy Training Application, and respond yes to the question about interest in this event. For those who have already completed applications, you will be automatically considered for this fall event and do not need to re-apply. Additional training retreats will be announced via the training newsletter as they are scheduled.
In January 2019, MAPS PBC submitted an MDMA-assisted psychotherapy for PTSD protocol to the U.S. Food and Drug Administration (FDA) as part of an application to participate in the FDA Expanded Access program. MAPS PBC is currently negotiating with FDA to gain clearance for the protocol. On May 16, 2019, FDA sent MAPS some comments on our proposed Expanded Access protocol. MAPS will respond in the next week or so, with a reply from FDA anticipated in early July 2019. The Expanded Access program’s purpose is to grant access to potentially beneficial investigational treatments for individuals or populations facing a serious or immediately life-threatening condition for which there is no satisfactory treatment currently available. If approved, Expanded Access would allow additional qualified sites to provide MDMA-assisted psychotherapy for participants with treatment-resistant PTSD under a MAPS protocol.
Sites in the U.S. and U.S. Territories interested in being considered to participate in an MDMA PTSD Expanded Access protocol, pending approval, may now apply with MAPS PBC to assess eligibility and obtain the prerequisite training to administer MDMA-assisted psychotherapy. The basic requirements of a qualified site are 1) Treatment Facility conducive to MDMA-assisted psychotherapy, 2) therapy team, qualified and able to complete MDMA Therapy Training Program, and 3) prescribing physician who can obtain a DEA Schedule 1 license for MDMA.
Site and practitioner application procedures are posted on our webpage. Each site must submit one site questionnaire. Additionally, each therapy provider must submit an MDMA Therapy Training Application for Therapy Providers. Only applicants affiliated with a qualifying site can be considered for training at this time. MAPS PBC will review applications on an ongoing basis, as they are received.
The MDMA Therapy Training Program takes seriously our obligation to participant safety and to reflecting internally to promote ethical growth and awareness surrounding diversity and inclusion. In service to this commitment, the MDMA Therapy Training Program presented the newly published MAPS MDMA-Assisted Therapy Code of Ethics to its trainees, and is implementing procedures to have therapy providers adhere to these ethical guidelines. The Code of Ethics can be found in the Spring 2019 edition of the MAPS Bulletin, Women and Psychedelics. MAPS has just posted a statement: Public Announcement of Ethical Violation by Former MAPS-Sponsored Investigators.
Additionally, trainees in the May cohort participated in a workshop on Power, Privilege, and Diversity led by Dr. Gaia Mika.
Sign up and stay tuned to the MDMA Therapy Training Program Newsletter to receive updates on upcoming trainings. • Learn More
Zendo Project: Lightning in a Bottle 2019 Recap, Upcoming Webinars, and Burning Man 2019
From May 8-13, 2019, Zendo Project staff and volunteers traveled to the Lightning in a Bottle festival at the Buena Vista Aquatic Recreational Area in Bakersfield, Calif., and provided psychedelic peer support for 164 attendees in need of compassionate care. The Zendo Project created comfortable spaces in two separate locations across the festival. The Zendo Project worked alongside RGX Medical, DanceSafe, Lightning in a Bottle Rangers, and High Rock Security to help maintain a safe environment for attendees. We would like to extend our gratitude to all of our volunteers and community for making our work possible.
From May 30 through June 27, you are invited to join the Zendo Project and harm reduction experts for Beyond Therapy: Psychedelics in Everyday Life. This 5-part weekly webinar series explores the topic of navigating psychedelic experiences beyond a therapy setting. In this unique online education series, you’ll learn how to provide support for people having difficult psychedelic experiences, how to access resources for safer partying and drug testing, and how to reduce the risks associated with psychedelics through preparation, integration, and ethics. Video recordings of each webinar will be provided to all registered attendees after the series concludes. Tickets are available for individual sessions or the full series. • Learn More
Zendo Project volunteer applications for Burning Man 2019 are now open! Interested applicants must secure their own Burning Man ticket. Our application pool is competitive, so please make sure your profile is as thorough and up-to-date as possible! • Apply Now
Support MAPS
April 2019 Giving Report: Raise Funds for MAPS European Studies
In April 2019, MAPS raised $90,190 in new donations and pledges from 796 generous supporters. Of that amount, $47,829 was for general support, $41,901 for MDMA/PTSD Phase 3, and $460 for other MAPS programs.
Currently, MAPS seeks $9 million for European Medicines Agency (EMA)-regulated trials to supplement the data gathered for the FDA, with $897,795 already raised and roughly $8.1 million still to go. We have completed key negotiations with EMA, and we will have a more precise estimate of timetables and costs for Phase 3 EMA trials in mid-2019 after completion of our negotiations with each country in the EMA in which we will have a Phase 3 site, and with each site.
We extend a special thanks to those who so generously supported MAPS last month:
General Support:
- Young Presidents’ Organization ($10,039)
- Yeonmi Park ($5,000)
- Jiri Techet ($3,000)
- Malkenson Foundation Inc. ($2,500)
- Ronald A. Mis ($1,290)
- Sonny Astani ($1,000)
- Ezekiel Golan $1,000)
MDMA/PTSD Phase 3 Research:
- KJC Intl. Research S.R.L. ($40,000)
Fiscal Sponsorship:
MAPS fiscally sponsors like-minded organizations and projects. This list includes donors who have contributed to organizations we fiscally sponsor.
- Cody Swift, RiverStyx Foundation ($34,000 – ICEERS)
- Nicole Panter Dailey ($5,555 – Prescription X)
- Jarrod Stanley ($2,500 – Chacruna)
- Todd Bureau ($1,000 – Prescription X)
- Dr. Sabrina Kay Charitable Foundation ($1,000 – Prescription X)
MAPS relies on the generosity of individual donors to achieve its mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate
Learn how to include MAPS in your will or estate plans.
Learn more about hosting a Global Psychedelic Dinner to fundraise for MAPS.
MAPS Receives $4,140,000 Grant from Psychedelic Science Funders Collaborative (PSFC)
The generosity of our supporters continues to humble us. The Psychedelic Science Funders Collaborative (PSFC) has generously provided a $4,140,000 grant to support the expansion of our work. PSFC is a non-profit network of philanthropists dedicated to supporting research and clinical trials with psychedelic medicines and patient access to these treatments. PSFC was born in 2017 out of a realization that psychedelic medicine has the potential to make an enormous impact and has an achievable path to regulatory approval, but has been systemically underfunded. With this grant to MAPS, PSFC is making its first big contribution.
“PSFC is committed to supporting MAPS in its quest to make MDMA-assisted psychotherapy legal and available for the millions of people suffering from PTSD around the globe. We applaud the incredible progress so far and are delighted to support the work to come,” says Joe Green, the President and Co-Founder of PSFC. Graham Boyd, Executive Director and Co-Founder of PSFC, adds: “We believe that regulatory approval of MDMA will be catalytic, clearing a path for other psychedelic medicines to address depression, addiction, and a range of other mental health conditions.”
The PSFC grant will advance some of the key objectives of the overall MAPS campaign to gain regulatory approval for MDMA and to ensure that patients have access to this critical medicine.
- $2,900,000 from PSFC for production of pharmaceutical-grade MDMA, made under current Good Manufacturing Practices (GMP) in a certified laboratory. A reliable supply of MDMA will support the clinical trials in the United States and Europe, as well as provide a supply for researchers around the globe. PSFC is also committed to helping MAPS scale production capacity to supply patient needs in the years to come.
- $1,100,000 from an anonymous PSFC member for European Medicines Agency (EMA)-regulated Phase 2 and Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD. MAPS and PSFC hope that approval in Europe and the United States will quickly translate into approval from other nations around the globe.
- $50,000 from PSFC to support MAPS’ work with Dr. Atul Pande. Dr. Pande will provide extended advisory support for the MAPS-sponsored clinical program and in planning for delivery of MDMA-assisted psychotherapy to patients. Dr. Pande has been involved with securing FDA and European Medicines Agency approval for over a dozen psychiatric drugs including Prozac, Lamictal, Lyrica, and Wellbutrin during his two decades of experience in roles such as Senior Vice President for Neurosciences at GlaxoSmithKline, Chief Medical Officer at PureTech Health, and others at large and small pharmaceutical companies.
- $50,000 from PSFC to support raising MAPS staff salaries. PSFC is excited to help MAPS staff receive compensation in line with the extraordinary work they are doing.
- $40,000 from PSFC for our upcoming Therapy Training Event for Communities of Color in Kentucky. PSFC believes strongly in the need to ensure access to treatment for underserved populations. In bringing forward a therapy that helps heal trauma, it is particularly important to ensure that therapists are trained who come from and serve in communities especially impacted by trauma, including communities of color.
Learn more about the Psychedelic Science Funders Collaborative (PSFC)
Media
Featured Media: May 2019
- PRESS RELEASE: Psychopharmacology Publishes Combined Analysis of Phase 2 Clinical Trials of MDMA-Assisted Therapy for PTSD
- Written on May 7, 2019
- The Guardian: Psychedelic Renaissance: Could MDMA Help With PTSD, Depression and Anxiety?
- Written by Jesse Noakes on April 14, 2019
- Business Insider: The 10 People Transforming Healthcare
- Written by Erin Brodwin, Emma Court and Lydia Ramsey on April 15, 2019
- Current Affairs: Make America Trip Again
- Written by Garrison Lovely on April 30, 2019
- HelloMD: MAPS Founder Rick Doblin Talks Psychedelics, MDMA and the FDA
- Written by Danielle Lim on May 10, 2019
- PsyPost: MDMA-Assisted Therapy for PTSD May Have Benefits Beyond Reductions in Clinical Symptoms
- Written by Eric W. Dolan on May 7, 2019
- Psychedelic Support: Visions to Heed: Ketamine’s Breakout In Psychedelic Therapy
- Written by Dan Bernitt on April 30, 2019
- Rolling Stone: Why Decriminalizing Magic Mushrooms in Denver Matters to the Rest of the Country
- Written by Shelby Hartman on May 11, 2019
- NBC: New Amsterdam
- Aired on May 14, 2019
MAPS Podcast
MAPS Podcast Episode 40 – David Jay Brown: A Legend in Psychedelic Consciousness
This episode of the MAPS podcast features a dynamic conversation with author David Jay Brown. Zach Leary has known David for over 30 years and has watched him dance with the legends of psychedelic culture, morphing into a legend all his own. From John Lilly to Albert Hofmann to Tim Leary, David always managed to extract the best from these brilliant minds and then build off of it to form his own magnificent insights into alternative culture and trans-personal evolution. Our conversations range from revisiting history to today’s psychedelic research and its mind expanding potentials.
David Jay Brown is an American writer, interviewer and consciousness researcher. Brown has studied parapsychology, and the effects of psychoactive drugs. With parapsychologist Rupert Sheldrake, he studied pets and people who apparently anticipate events. Brown has served as a guest editor and he has published many interviews of prominent thinkers. • Listen Now
MAPS Psychedelic Bibliography
Psychedelic Bibliography
The MAPS Psychedelic Bibliography is a searchable database of over 12,000 publications of psychedelic literature, scientific research, and popular culture articles, with a special focus on scientific papers about LSD and psilocybin. Each record consists of a title, author name or names, and often an abstract or notes about the piece. The bibliography allows people to learn more about where psychedelic science has been while keeping up to date on where it is going now. The Psychedelic Bibliography is an excellent resource for professional authors, university students, or MAPS fans seeking general information on the history of psychedelics. • Browse the Bibliography
MAPS Store
The Science of Microdosing Psychedelics by Torsten Passie, M.D.
Less is more? Extraordinary claims about the effects of microdosing psychedelic substances include the ability to enhance creativity, elevate mood and even combat depression. In The Science of Microdosing Psychedelics, Dr. Torsten Passie reveals a rich and largely ignored history of research with microdose, minidose and low-dose LSD, and other psychedelics.
With microdosing being lauded across the media as a potential panacea, this carefully researched and comprehensive book covers key areas such as tolerance, toxicity, and placebo. It also includes newly translated and never before referenced LSD studies. A book no discerning researcher, practitioner or psychedelic aficionado should be without. • Buy Now
MAPS Laptop Sleeve
Proudly support MAPS’ research and keep your laptop safe with these MAPS Laptop Sleeves! These neoprene cases feature a zippered main pocket to safely carry any laptop up to 15 inches, and zippered front pocket for your accessories. Each of the laptop sleeves are screen printed with the MAPS logo. • Buy Now
Events
Browse our Event Calendar page for more opportunities.
Canna West Summit 2019, May 29-31, 2019, Los Angeles, California
Now in its 6th chapter, Infocast’s Canna WEST Summit returns with its unique cross-section of policy, health, and technical regulators from dozens of states. These regulators will engage with cannabis operators, testing and quality professionals, and solution providers. This is the place where innovators, advocates, and compliance consultants can sit down with policy leaders and compliance enforcers, understand their priorities, and in turn educate them on the unique needs and issues of the highly innovative cannabis culture and medical eco-system. • MAPS supporters receive 10% off registration with this coupon code: 192231
World Ayahuasca Conference 2019, Girona, Spain, May 31 – June 2, 2019
Join us in Girona, in the beautiful region of Catalonia (Spain), to celebrate the diversity of ayahuasca cultures, practices, art, film, and research. AYA2019 will be more than a conference. It will be the largest event ever held about ayahuasca, one where we inspire each other to work together for a more connected, meaningful, and sustainable life on earth. • Learn More
Queering Psychedelics, June 1-2, 2019, San Francisco, California
This 2-day conference is part of Chacruna’s Women, Gender Diversity, and Sexual Minorities speaker series. It highlights the voices of queer visionaries within the psychedelic community as well as examines the history of psychedelics from queer and non-binary perspectives. As the so-called psychedelic renaissance reaches a pivotal moment of mainstream interest and regulatory legitimacy, it is vital that traditionally underrepresented communities share a seat at the table and have their voices heard so as to ensure access to all the benefits that psychedelics and plant medicine offer. • Learn More
Women’s Visionary Congress, Oakland, California, June 14-16, 2019
The 11th annual Women’s Visionary Congress (WVC) is a public discussion of new ideas for resilience and sustainability with more than twenty speakers. A non-profit organization, the Women’s Visionary Council (WVC) promotes women who develop innovative mental health and community wellness services, hosts public discussions including the Women’s Visionary Congress, and makes grants to advance the work of women healers, researchers, activists, and artists at the leading edge of cultural evolution. • Learn More
Breaking Convention 2019, August 16-18, 2019, London, United Kingdom
Breaking Convention is a biennial multidisciplinary conference on psychedelic consciousness, featuring more than 150 presenters from around the world. Europe’s largest conference on psychedelic consciousness, Breaking Convention is now approaching its eighth year. Breaking Convention is a truly multi-faceted festival selling nearly a thousand tickets in forty countries and offering the latest ground-breaking research and insights across human and social sciences, law, politics, art, history and philosophy. Spanning three full days, Breaking Convention features numerous workshops, awards, an art exhibition, and films. • Learn More
Horizons: Perspectives on Psychedelics 2019, October 11-13, 2019, New York, New York
Horizons: Perspectives on Psychedelics is an annual forum in New York City that examines the role of psychedelic drugs and plant medicines in science, medicine, culture and spirituality. In recent years, a growing community of scientists, doctors, scholars, and activists have orchestrated a renaissance in psychedelic research and practice. Horizons brings together the brightest minds and the boldest voices of this movement to share their knowledge, insights, and dreams for the future. Now in its twelfth year, Horizons is the largest and longest-running annual gathering of the psychedelic community in the world. • Learn More
Psychedelics for Clinicians 101 & 102, November 2-3, 2019, Montreal, Canada
This 2-day training offered by psychologists Ingmar Gorman and Elizabeth Nielson is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes experiential learning and role-play exercises. It is the first time a program of this kind has been offered in Montreal. • Learn More
International Drug Policy Reform Conference, November 6-9, 2019, St. Louis, Missouri
The International Drug Policy Reform Conference is a biennial event that brings together people from around the world who believe that the war on drugs must end. Reform attendees have the opportunity to spend three days interacting with people committed to finding alternatives to the war on drugs while participating in sessions given by leading experts from around the world. • Learn More
Participate in Psychedelic Reseearch
MDMA Studies Supported by MAPS
MAPS sponsors clinical trials around the world that require human participants. Our studies have strict enrollment criteria based on the goal of the study and the condition the study is investigating.
Phase 3 trial participant enrollment is now open. Please bookmark our Participate in Research page and check it frequently for updates.
Psychedelic Use, Compassion, and Life Satisfaction Study
Arizona State University is gathering information on psychedelic drug use and overall life satisfaction. We are currently looking for individuals who have had psychedelic experiences, and those who are lifelong abstainers. To participate, you must be at least 18 years old. This study will consist of two parts. Upon completion, you will be entered into a drawing to win 1 of several gift cards worth up to $99. • Take the Survey
Cannabis Survey
The aim of this study is to help to develop a model for the sale of cannabis in the United Kingdom. The study aims to address many questions regarding the sale of cannabis for both medical and recreational use in the UK. The survey should take about 20 minutes to complete.• Take the Survey
Military and Veteran Perceptions of Psychedelics Survey
Austin Peay State University researchers Roxanne Hallisey and Dr. Emily Pica are conducting a study about military and veteran perceptions of psychedelics. The survey takes about 40 minutes to complete and asks for the voluntary participation of United States military members and veterans. • Take the Survey
Psychedelic Culture Survey
The Limina Foundation is conducting an anonymous survey about today’s psychedelic culture. • Take the Survey
More News
Statement: Public Announcement of Ethical Violation by Former MAPS-Sponsored Investigators
This is a public announcement of ethical violations committed by former sub-investigators who previously provided therapy on a MAPS-sponsored clinical trial. The contents of this statement may be potentially triggering to those who have suffered from ethical violations and trauma of a sexual nature. We intend our making this information public to be part of our effort to eliminate future ethical violations by these and any other prior, current, or future therapists working for MAPS. • Read More
Source Research Foundation Grants for Students
Source Research Foundation is offering up to $10,000 in grants for students with research proposals to expand the field of psychedelic science. • Learn More
We’re Hiring!
MAPS and MAPS Public Benefit Corporation (MAPS PBC) are currently hiring! MAPS is hiring a Chief Operations Officer (COO). MAPS PBC is hiring a Video Systems Manager and Clinical Research Associate. You can support MAPS by referring qualified applicants to our open positions.
Thank you to Dr. Bronner’s for their company’s support of the MAPS Newsletter!